Apoptosis inducers in chronic lymphocytic leukemia

Christian Billard

doi:10.18632/oncotarget.1480

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Apoptosis inducers in chronic lymphocytic leukemia

Christian Billard _

PDF | HTML | How to cite

Oncotarget. 2014; 5:309-325. https://doi.org/10.18632/oncotarget.1480

Metrics: PDF 3871 views | HTML 5372 views | ?

Abstract

Christian Billard1,2

1 INSERM U 872, Centre de Recherche des Cordeliers, Equipe 18, Paris, France

2 Université Pierre et Marie Curie (UMRS 872), Paris, France.

Correspondence:

Christian Billard, email:

Keywords: CLL; impaired cell death program; apoptosis-targeted therapies; apoptosis inducers; Bcl-2 family proteins.

Received: October 8, 2013 Accepted: November 18, 2013 Published: November 19, 2013

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by a typical defect in apoptosis and is still an incurable disease. Numerous apoptosis inducers have been described. These synthetic compounds and natural products (mainly derived from plants) display antileukemic properties in vitro and in vivo and some have even been tested in the clinic in CLL. They act through several different mechanisms. Most of them involve proteins of the Bcl-2 family, which are the key regulators in triggering the mitochondrial pathway of caspase-dependent apoptosis. Thus, the Mcl-1/Noxa axis appeared as a target. Here I overview natural and synthetic apoptosis inducers and their mechanisms of action in CLL cells. Opportunities for developing novel, apoptosis-based therapeutics are presented.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 1480

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Apoptosis inducers in chronic lymphocytic leukemia

Abstract